Evidence map›Paper›PMID 39766067›Full record

ArticleCancers2024

RETRACTED: Pneumonia in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax-Based Regimens: A Real-World Analysis of the Polish Adult Leukemia Group (PALG).

Elżbieta Kalicińska, Paula Jabłonowska-Babij, Marta Morawska, Elżbieta Iskierka-Jażdżewska, Joanna Drozd-Sokołowska, Ewa Paszkiewicz-Kozik, Łukasz Szukalski, Judyta Strzała, Urszula Gosik, Jakub Dębski and 4 more

RetractedAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Elżbieta KalicińskaClinical Department of Hematology, Cell Therapies and Internal Diseases, Wroclaw Medical University, 50-367 Wroclaw, Poland.ORCID 0000-0002-4797-8001
Paula Jabłonowska-BabijClinical Department of Hematology, Cell Therapies and Internal Diseases, Wroclaw Medical University, 50-367 Wroclaw, Poland.ORCID 0000-0001-6984-2116
Marta MorawskaExperimental Hematooncology Department, Medical University of Lublin, 20-059 Lublin, Poland.ORCID 0000-0001-6836-2903
Elżbieta Iskierka-JażdżewskaDepartment of General Hematology, Copernicus Memorial Hospital, Medical University of Lodz, 90-419 Lodz, Poland.
Joanna Drozd-SokołowskaDepartment of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland.ORCID 0000-0002-4562-6264
Ewa Paszkiewicz-KozikDepartment of Lymphoid Malignancies, National Research Institute of Oncology, 02-781 Warsaw, Poland.
Łukasz SzukalskiDepartment of Hematology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, 85-168 Toruń, Poland.
Judyta StrzałaDepartment of Hematology and Bone Marrow Transplantation, Pomeranian Hospitals in Gdynia, 81-519 Gdynia, Poland.ORCID 0009-0002-4476-9703
Urszula GosikDepartment of Hematology, St. John's Cancer Center in Lublin, 20-090 Lublin, Poland.
Jakub DębskiDepartment of Hematology, Provincial Specialist Hospital in Legnica, 59-220 Legnica, Poland.
Iga AndrasiakIndividual Business Activity, ul. Zielna 28b/3, 51-313 Wroclaw, Poland.ORCID 0000-0002-8415-8758
Anna SkotnyHarvard T.H. Chan School of Public Health-Executive and Continuing Education, Harvard University, Boston, MA 02115, USA.ORCID 0000-0003-4167-0572
Krzysztof JamroziakDepartment of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland.
Tomasz WróbelClinical Department of Hematology, Cell Therapies and Internal Diseases, Wroclaw Medical University, 50-367 Wroclaw, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesPatients with chronic lymphocytic leukemia (CLL) are susceptible to infections that can affect their clinical outcomes.

aimsThe aims of this study were to assess the following: (1) the incidence of pneumonia in CLL patients treated with venetoclax-based regimens in a real-world setting, (2) the risk factors for event-free survival (EFS), and (3) overall survival (OS).

methodsThis multicenter study included 322 patients from eight centers. Univariable and multivariable analyses (MVA) were performed, with the development of pneumonia during venetoclax-based treatment and OS as outcomes.

resultsThe most common complication was neutropenia (59%). During treatment with venetoclax-based regimens, 66 (20%) patients developed pneumonia-50 (23%) patients in the rituximab-plus-venetoclax (R-VEN) group and 13 (16%) patients in the obinutuzumab-plus-venetoclax (O-VEN) group (

conclusionsOur real-world study showed that pneumonia during venetoclax treatment occurs more frequently than reported in registration trials and has a negative impact on OS, especially in patients with R/R CLL who are treated with R-VEN. Neutropenia is not a risk factor for pneumonia.

Indexed as

CLLinfectionoverall survivalpneumoniavenetoclax

Identifiers

PMID39766067
PMCPMC11674704

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.